The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase

(2013) Peter K. Quashie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir

(2013) Wei Huang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dolutegravir: First Global Approval

(2013) Anita D. Ballantyne et al.   DRUGS

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

(2013) Anne-Geneviève Marcelin et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

(2013) Thibault Mesplède et al.   Retrovirology

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens

(2012) Carolina Garrido et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dolutegravir for the treatment of HIV

(2012) Christine Katlama et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Resistance to HIV integrase inhibitors

(2012) Thibault Mesplède et al.   Current Opinion in HIV and AIDS

HIV Drug Resistance and the Advent of Integrase Inhibitors

(2012) Peter K. Quashie et al.   Current Infectious Disease Reports

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

(2011) Kendra E. Hightower et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir

(2011) P. K. Quashie et al.   JOURNAL OF VIROLOGY

Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

(2011) H.-T. Xu et al.   JOURNAL OF VIROLOGY

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

(2011) Jean-Michel Molina et al.   LANCET INFECTIOUS DISEASES

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays

(2010) Tamara Bar-Magen et al.   AIDS

Secondary Integrase Resistance Mutations Found in HIV-1 Minority Quasispecies in Integrase Therapy-Naive Patients Have Little or No Effect on Susceptibility to Integrase Inhibitors

(2010) F. Ceccherini-Silberstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Resistance to HIV-1 integrase inhibitors: A structural perspective

(2010) Jean-François Mouscadet et al.   DRUG RESISTANCE UPDATES

Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors

(2009) A. Low et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET